| P2093 | author name string | George L Bakris | |
| | Rigas G Kalaitzidis | |
| P2860 | cites work | Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure | Q22306384 |
| | Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes | Q28188162 |
| | Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization | Q28283679 |
| | Prevalence of chronic kidney disease in the United States | Q29614191 |
| | Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy | Q29615215 |
| | Telmisartan, ramipril, or both in patients at high risk for vascular events | Q33156143 |
| | Efficacy and safety of benazepril for advanced chronic renal insufficiency | Q33992851 |
| | Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis | Q36336393 |
| | Combination therapy with aldosterone blockade and renin-angiotensin inhibitors confers organ protection | Q36508380 |
| | Influence of albuminuria and glomerular filtration rate on blood pressure response to antihypertensive drug therapy | Q36596862 |
| | Antihypertensive therapy in the presence of proteinuria | Q36690664 |
| | Appropriate blood pressure control in hypertensive and normotensive type 2 diabetes mellitus: a summary of the ABCD trial | Q36891898 |
| | Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review | Q37063760 |
| | Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D). | Q37087865 |
| | Hypertensive nephrosclerosis | Q37137413 |
| | Influence of microalbuminuria in achieving blood pressure goals | Q37241562 |
| | Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study | Q40394575 |
| | Predictors of hyperkalemia risk following hypertension control with aldosterone blockade | Q43279459 |
| | Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial | Q44218873 |
| | Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis | Q44579295 |
| | Changes in insulin sensitivity, renal function, and markers of endothelial dysfunction in hypertension--the impact of microalbuminuria: a 13-year follow-up study | Q46121987 |
| | The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension | Q46169157 |
| | Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. | Q46426098 |
| | Renin-angiotensin blockade and kidney disease | Q46426114 |
| | Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLH | Q46455413 |
| | Effects of renin-angiotensin system blockers on renal outcomes and all-cause mortality in patients with diabetic nephropathy: an updated meta-analysis | Q46555031 |
| | Aliskiren combined with losartan in type 2 diabetes and nephropathy | Q46558669 |
| | Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria | Q46654200 |
| | KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. | Q55043049 |
| | 2007 Guidelines for the Management of Arterial Hypertension | Q56970780 |
| | Albuminuria Is a Target for Renoprotective Therapy Independent from Blood Pressure in Patients with Type 2 Diabetic Nephropathy: Post Hoc Analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) Trial | Q57702534 |
| | Glomerular Filtration Rate, Cardiorenal End Points, and All-Cause Mortality in Type 2 Diabetic Patients | Q58209768 |
| | Lack of association between endothelial nitric oxide synthase gene polymorphisms, microalbuminuria and endothelial dysfunction in hypertensive men | Q61684829 |
| | The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group | Q70513402 |
| | Blood pressure and end-stage renal disease in men | Q71574790 |
| | Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study | Q71777734 |
| | Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia) | Q73499190 |
| | Controversy about COOPERATE ABPM trial data | Q79605302 |
| | Microalbuminuria and chronic kidney disease as risk factors for cardiovascular disease | Q79748618 |
| | K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease | Q80010742 |
| | Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency | Q80313261 |
| | Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes | Q80797117 |
| | The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study | Q81454959 |
| | Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease | Q81555894 |
| P433 | issue | 6 | |
| P921 | main subject | arterial hypertension | Q41861 |
| P304 | page(s) | 436-442 | |
| P577 | publication date | 2009-11-01 | |
| P1433 | published in | Current cardiology reports | Q26842345 |
| P1476 | title | The current state of RAAS blockade in the treatment of hypertension and proteinuria | |
| P478 | volume | 11 | |